Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29642529 | 1.00 | AKR1C3 (0.42) | AKR1C3AKR1C1SMN1; SMN2GAAMAPT | |
| SCHEMBL16582761 | 1.00 | AKR1C3 (0.42) | AKR1C3AKR1C1SMN1; SMN2GAAMAPT | |
| SCHEMBL16568791 | 1.00 | AKR1C3 (0.42) | AKR1C3AKR1C1SMN1; SMN2GAAMAPT | |
| SCHEMBL8779972 | 1.00 | AKR1C3 (0.42) | AKR1C3AKR1C1SMN1; SMN2GAAMAPT | |
| SCHEMBL6568328 | 0.75 | TP53 (0.45) | SMN1; SMN2GAAALDH1A1HPGDHSD17B10 | |
| SCHEMBL16582723 | 0.69 | AKR1C3 (0.36) | AKR1C3AKR1C1GAAMAPTALDH1A1 | |
| SCHEMBL21558150 | 0.69 | AKR1C3 (0.36) | AKR1C3AKR1C1GAAMAPTALDH1A1 | |
| SCHEMBL16582715 | 0.69 | AKR1C3 (0.36) | AKR1C3AKR1C1GAAMAPTALDH1A1 | |
| SCHEMBL8779970 | 0.69 | F2 (0.42) | SMN1; SMN2LMNA | |
| SCHEMBL10843954 | 0.69 | SMN1; SMN2 (0.65) | SMN1; SMN2GAAMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9831448-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-11-28 | — | — | US | disclosed |
| US-9831448-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-11-28 | — | — | US | disclosed |
| US-20160233443-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160233443-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160233443-A1 | Metal Complexes | AP1M1, SOD1, AP3M1 | AKR1C3 4439/4885AKR1C1 4294/4885SMN1; SMN2 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.